| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/17/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 01/12/2023 | — | Canaccord Genuity | Downgrades | Buy → Hold | |
| 05/16/2022 | 1233.33% | Aegis Capital | $35 → $30 | Maintains | Buy |
| 02/18/2022 | 788.89% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 11/30/2021 | 1322.22% | HC Wainwright & Co. | $17 → $32 | Maintains | Buy |
| 11/29/2021 | 1322.22% | HC Wainwright & Co. | $17 → $32 | Maintains | Buy |
| 11/02/2021 | 1455.56% | Aegis Capital | $20 → $35 | Maintains | Buy |
| 07/29/2021 | 1233.33% | Canaccord Genuity | $27 → $30 | Maintains | Buy |
| 06/08/2021 | 788.89% | Aegis Capital | $12 → $20 | Maintains | Buy |
| 04/20/2021 | 1100% | Canaccord Genuity | → $27 | Initiates Coverage On | → Buy |
| 02/09/2021 | 922.22% | National Securities Corporation | → $23 | Initiates Coverage On | → Buy |
| 01/27/2021 | 433.33% | Aegis Capital | $6 → $12 | Maintains | Buy |
| 07/13/2020 | 655.56% | HC Wainwright & Co. | $16 → $17 | Reiterates | → Buy |
| 06/22/2020 | 611.11% | HC Wainwright & Co. | $20 → $16 | Maintains | Buy |
| 09/11/2019 | 211.11% | Ladenburg Thalmann | → $7 | Initiates Coverage On | → Buy |
What is the target price for Oramed Pharmaceuticals (ORMP)?
The latest price target for Oramed Pharmaceuticals (NASDAQ: ORMP) was reported by HC Wainwright & Co. on January 17, 2023. The analyst firm set a price target for $0.00 expecting ORMP to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Oramed Pharmaceuticals (ORMP)?
The latest analyst rating for Oramed Pharmaceuticals (NASDAQ: ORMP) was provided by HC Wainwright & Co., and Oramed Pharmaceuticals downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Oramed Pharmaceuticals (ORMP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on January 17, 2023 so you should expect the next rating to be made available sometime around January 17, 2024.
Is the Analyst Rating Oramed Pharmaceuticals (ORMP) correct?
While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a downgraded with a price target of $0.00 to $0.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $2.25, which is out of the analyst's predicted range.